GIP and GLP-1 Dual Agonism: How Tirzepatide Works

Key Point 1Tirzepatide is a dual agonist, targeting both GIP and GLP-1 receptors, enhancing its effects on blood sugar and weight loss.

Key Point 2GLP-1 receptor agonists primarily focus on stimulating insulin release and reducing appetite, while Tirzepatide adds the benefits of GIP receptor activation.

Key Point 3Clinical trials show that Tirzepatide can lead to more significant weight loss compared to GLP-1 receptor agonists alone.

Key Point 4Hi Doctor AI provides a convenient way to access consultations with EU-licensed doctors for weight management and potential Tirzepatide prescriptions.

Understanding GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used to treat type 2 diabetes and obesity. These drugs mimic the effects of the natural GLP-1 hormone, which is released in the gut after eating. GLP-1 receptor agonists work by:

• Stimulating insulin release from the pancreas, which helps lower blood sugar levels.
• Slowing down gastric emptying, which can reduce appetite and increase feelings of fullness.
• Reducing the secretion of glucagon, a hormone that raises blood sugar levels.

Common GLP-1 receptor agonists include semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda). These medications have been shown to be effective in promoting weight loss and improving blood sugar control in individuals with type 2 diabetes.

The Role of GIP Receptors

Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone, similar to GLP-1. It is also released from the gut in response to food intake and plays a role in regulating blood sugar and energy balance. GIP receptors are found in various tissues throughout the body, including the pancreas, brain, and adipose tissue. Activation of GIP receptors can:

• Enhance insulin secretion from the pancreas.
• Reduce appetite and increase feelings of satiety.
• Improve insulin sensitivity.
• Potentially increase energy expenditure.

While GLP-1 receptor agonists have been successful in treating diabetes and obesity, researchers have explored the potential benefits of targeting both GIP and GLP-1 receptors simultaneously.

Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist

Tirzepatide is a novel medication that acts as a dual agonist, meaning it activates both GIP and GLP-1 receptors. This dual action is believed to enhance its effectiveness in regulating blood sugar and promoting weight loss compared to GLP-1 receptor agonists alone. By targeting both pathways, Tirzepatide can:

• Maximize insulin secretion in a glucose-dependent manner.
• Potentiate appetite reduction and promote satiety.
• Improve overall metabolic function.

Clinical trials have demonstrated that Tirzepatide can lead to significant weight loss and improved blood sugar control in individuals with type 2 diabetes and obesity. Studies have shown that Tirzepatide can result in an average weight loss of 15-20% of initial body weight, which is notably higher than what is typically observed with GLP-1 receptor agonists.

Clinical Evidence and Results

The efficacy of Tirzepatide has been evaluated in several clinical trials. The SURPASS trials, for example, compared Tirzepatide to other diabetes medications, including semaglutide. The results showed that Tirzepatide led to greater reductions in HbA1c (a measure of average blood sugar levels) and body weight compared to semaglutide and other treatments.

In the SURMOUNT-1 trial, which focused on individuals with obesity but without diabetes, Tirzepatide demonstrated remarkable weight loss results. Participants receiving the highest dose of Tirzepatide experienced an average weight loss of 22.5% over 72 weeks. These findings highlight the potential of Tirzepatide as a powerful tool for weight management.

Hi Doctor AI provides telemedicine consultations. All treatments are prescribed by EU-licensed doctors after reviewing your medical history. We do not sell or ship medications—prescriptions can be used at any licensed pharmacy in the EU.

Like all medications, Tirzepatide may cause side effects. Common side effects include nausea, diarrhea, vomiting, and constipation. These side effects are typically mild to moderate and tend to improve over time. It is important to discuss any concerns or potential side effects with your doctor before starting Tirzepatide.

How Hi Doctor AI Helps

Hi Doctor AI offers a convenient and accessible way to explore weight management options, including potential prescriptions for medications like Tirzepatide. Our EU-licensed doctors conduct online consultations to assess your medical history and determine if Tirzepatide is appropriate for you. With Hi Doctor AI:

• You can skip the waiting room and consult with a doctor from the comfort of your home.
• Our consultations are conducted online, with no video call required.
• If deemed suitable, you can receive a valid EU prescription in less than 24 hours.
• We offer a 45€ consultation fee, with a full refund if no prescription is issued.

Ready to Start?

Tirzepatide represents a significant advancement in the treatment of obesity and type 2 diabetes. Its dual action on both GIP and GLP-1 receptors offers enhanced benefits compared to GLP-1 receptor agonists alone. Clinical trials have demonstrated its effectiveness in promoting substantial weight loss and improving blood sugar control.

Ready to start your weight loss journey? Get your online consultation with Hi Doctor AI—EU-licensed doctors, 45€ consultation fee.